이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib (ELRISE MF)

2026년 8월 20일 업데이트: Takeda

A Phase 3, Double-Blind, Randomized Trial Evaluating the Efficacy and Safety of Elritercept (TAK-226) Compared to Placebo in Participants With Myelofibrosis and Anemia on Concurrent Ruxolitinib Therapy

The main aim of this study is to find out how well elritercept works to improve anemia in participants with myelofibrosis (MF) who are taking ruxolitinib when compared to placebo.

Other aims are to learn how elritercept improves anemia compared to placebo; to learn if elritercept reduces tiredness, improves symptoms related to MF, and helps participants do physical activities more easily. The study also aims to find out how elritercept affects the bone marrow, the spleen, and whether participants develop antibodies to the study drug.

The study will also check how safe elritercept is compared to placebo, and if elritercept stays safe over a long period of time. Participants will receive study treatment for at least 9 months (36 weeks). After this period, participants who received placebo will have the option to switch to elritercept.

연구 개요

상태

모병

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

324

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

  • 그리스
    • Ahaia
      • Pátrai, Ahaia, 그리스, 264 43
        • 아직 모집하지 않음
        • Olympion General Clinic & Rehabilitation Center
        • 수석 연구원:
          • Argiris Symeonidis
        • 연락하다:
    • Attica
      • Athens, Attica, 그리스, 11528
        • 아직 모집하지 않음
        • Alexandra General Hospital of Athens
        • 수석 연구원:
          • Meletios-Athanasios Dimopoulos
        • 연락하다:
      • Athens, Attica, 그리스, 11526
        • 아직 모집하지 않음
        • Laiko General Hospital of Athens
        • 수석 연구원:
          • Theodoros Vassilakopoulos
        • 연락하다:
      • Athens, Attica, 그리스, 11527
        • 아직 모집하지 않음
        • General Hospital
        • 수석 연구원:
          • Panagiotis Diamantopoulos
        • 연락하다:
    • Crete
      • Heraklion, Crete, 그리스, 70013
        • 아직 모집하지 않음
        • University of Crete
        • 연락하다:
        • 수석 연구원:
          • Nikolaos Sousos
    • Macedonia
      • Thessaloniki, Macedonia, 그리스, 54642
        • 아직 모집하지 않음
        • Ippokrateion Hospital of Thessaloniki
        • 연락하다:
        • 수석 연구원:
          • Eleni Gavriilaki
  • 대만
      • Kaohsiung City, 대만
        • 아직 모집하지 않음
        • Kaohsiung Medical University Hospital
        • 수석 연구원:
          • Yi-Chang Liu
        • 연락하다:
      • Taichung, 대만, 40705
        • 아직 모집하지 않음
        • Taichung Veterans General Hospital
        • 연락하다:
        • 수석 연구원:
          • Tsung Chih Chen
      • Tainan, 대만, 70403
        • 아직 모집하지 않음
        • National Cheng Kung University Hospital
        • 수석 연구원:
          • Tsai-Yun Chen
        • 연락하다:
    • Beitou
      • Taipei, Beitou, 대만, 11217
        • 아직 모집하지 않음
        • Taipei Veterans General Hospital
        • 수석 연구원:
          • Chih-Cheng Chen
        • 연락하다:
    • Taiwan (r.o.c.)
      • Taipei, Taiwan (r.o.c.), 대만, 100
        • 아직 모집하지 않음
        • National Taiwan University Hospital
        • 수석 연구원:
          • Hsin-An Hou
        • 연락하다:
  • 대한민국
      • Daegu, 대한민국, 42472
        • 아직 모집하지 않음
        • Daegu Catholic University Medical Center
        • 수석 연구원:
          • Sung Hwa Bae
        • 연락하다:
      • Seoul, 대한민국, 3080
        • 아직 모집하지 않음
        • Seoul National University Hospital
        • 수석 연구원:
          • Junshik Hong
        • 연락하다:
      • Seoul, 대한민국, 137-701
        • 아직 모집하지 않음
        • The Catholic University of Korea
        • 수석 연구원:
          • Sung-Eun Lee
        • 연락하다:
    • Gangnam-gu
      • Seoul, Gangnam-gu, 대한민국
        • 아직 모집하지 않음
        • Samsung Medical Center
        • 연락하다:
        • 수석 연구원:
          • Chul Won Jung
    • Gyeonggi-do
      • Seongnam-si, Gyeonggi-do, 대한민국, 13620
        • 아직 모집하지 않음
        • Seoul National University Bundang Hospital
        • 수석 연구원:
          • Soo-Mee Bang
        • 연락하다:
    • Seongbuk-gu
      • Seoul, Seongbuk-gu, 대한민국
        • 아직 모집하지 않음
        • Korea University Anam Hospital
        • 수석 연구원:
          • Yong Park
        • 연락하다:
    • Seoul Teugbyeolsi
      • Seoul, Seoul Teugbyeolsi, 대한민국, 04401
        • 아직 모집하지 않음
        • Soon Chun Hyang University Hospital Seoul
        • 수석 연구원:
          • Seug Yun Yoon
        • 연락하다:
  • 독일
      • Berlin, 독일, 10715
    • Baden-Wurttemberg
      • Freiburg im Breisgau, Baden-Wurttemberg, 독일, 79106
        • 아직 모집하지 않음
        • Universitaetsklinikum Freiburg
        • 연락하다:
        • 수석 연구원:
          • Heiko Becker
      • Heidelberg, Baden-Wurttemberg, 독일, 69120
        • 아직 모집하지 않음
        • Universitaetsklinikum Heidelberg (UKHD)
        • 연락하다:
        • 수석 연구원:
          • Tim Sauer
      • Mutlangen, Baden-Wurttemberg, 독일, 73557
        • 아직 모집하지 않음
        • Kliniken Ostalb
        • 수석 연구원:
          • Holger Hebart
        • 연락하다:
    • North Rhine-Westphalia
      • Minden, North Rhine-Westphalia, 독일, 32429
        • 아직 모집하지 않음
        • Muehlenkreiskliniken AoeR-Johannes Wesling Klinikum Minden - Universitaetsklinik fuer Neurologie und Neurogeriatrie
        • 수석 연구원:
          • Martin Griesshammer
        • 연락하다:
    • Rhineland-Palatinate
      • Koblenz, Rhineland-Palatinate, 독일, 56068
        • 아직 모집하지 않음
        • Institut fur Versorgungsforschung in der Onkologie GbR
        • 연락하다:
        • 수석 연구원:
          • Cristoph Lutz
    • Saxony
      • Chemnitz, Saxony, 독일, 9116
        • 아직 모집하지 않음
        • Klinikum Chemnitz GmbH
        • 수석 연구원:
          • Mathias Hanel
        • 연락하다:
    • Saxony-Anhalt
      • Halle, Saxony-Anhalt, 독일, 06120
        • 아직 모집하지 않음
        • University Hospital Halle (Saale)
        • 수석 연구원:
          • Haifa Kathrin Al-Ali
        • 연락하다:
    • Thuringia
      • Jena, Thuringia, 독일, 7743
        • 아직 모집하지 않음
        • Universitaetsklinikum Jena
        • 수석 연구원:
          • Carl Crodel
        • 연락하다:
  • 루마니아
      • Bucharest, 루마니아, 20125
        • 아직 모집하지 않음
        • Colentina Clinical Hospital
        • 수석 연구원:
          • Mihaela Andreescu
        • 연락하다:
      • Timișoara, 루마니아, 300700
        • 아직 모집하지 않음
        • Spitalul Clinic Municipal de Urgenta Timisoara
        • 연락하다:
        • 수석 연구원:
          • Ioana Ionita
    • CJ
      • Cluj-Napoca, CJ, 루마니아, 400124
        • 아직 모집하지 않음
        • Institutul Oncologic Prof. Dr. Ion Chiricuta
        • 수석 연구원:
          • Ciprian Tomuleasa
        • 연락하다:
    • Dolj
      • Craiova, Dolj, 루마니아, 200143
        • 아직 모집하지 않음
        • Spitalul Municipal Filantropia Craiova
        • 수석 연구원:
          • Luminita Ocroteala
        • 연락하다:
  • 말레이시아
    • Kuala Lumpur
      • Kuala Lumpur, Kuala Lumpur, 말레이시아, 59100
        • 아직 모집하지 않음
        • University Malaya Medical Centre
        • 연락하다:
        • 수석 연구원:
          • Edmund Fui Min Chin
    • Pulau Pinang
      • George Town, Pulau Pinang, 말레이시아, 10990
        • 아직 모집하지 않음
        • Hospital Pulau Pinang
        • 연락하다:
        • 수석 연구원:
          • Hong Keng Liew
    • Sabah
      • Kota Kinabalu, Sabah, 말레이시아, 88586
        • 아직 모집하지 않음
        • Hospital Queen Elizabeth
        • 연락하다:
        • 수석 연구원:
          • Khaiteri Raghunathan
    • Selangor
      • Ampang, Selangor, 말레이시아, 68000
        • 아직 모집하지 않음
        • Hospital Ampang
        • 수석 연구원:
          • Veena Selvaratnam
        • 연락하다:
  • 멕시코
    • Mexic
      • Monterrey, Mexic, 멕시코, 64710
        • 아직 모집하지 않음
        • Universidad Autonoma de Nuevo Leon
        • 수석 연구원:
          • David Gomez Almaguer
        • 연락하다:
    • Mexico de Mexico
      • Huixquilucan, Mexico de Mexico, 멕시코, 52787
        • 아직 모집하지 않음
        • Hematologica Alta Especialidad S.C.
        • 연락하다:
        • 수석 연구원:
          • Roberto Ovilla Martinez
    • Oaxaca
      • Oaxaca City, Oaxaca, 멕시코, 68000
        • 아직 모집하지 않음
        • OSMO - Oaxaca Site Management Organization S.C
        • 연락하다:
        • 수석 연구원:
          • Eva Ramirez Romero
  • 미국
    • Arizona
      • Gilbert, Arizona, 미국, 85234
        • 아직 모집하지 않음
        • Banner MD Anderson Cancer Center
        • 수석 연구원:
          • Mark Faber
        • 연락하다:
    • California
      • Glendale, California, 미국, 91204
        • 아직 모집하지 않음
        • Los Angeles Cancer Network
        • 연락하다:
        • 수석 연구원:
          • Saro Kasparian
      • Whittier, California, 미국, 90603
        • 아직 모집하지 않음
        • Cancer and Blood Specialty Clinic
        • 수석 연구원:
          • Merrill Shum
        • 연락하다:
    • District of Columbia
      • Washington D.C., District of Columbia, 미국, 20007
        • 아직 모집하지 않음
        • MedStar Georgetown University Hospital
        • 연락하다:
        • 수석 연구원:
          • Julia Cunningham
    • Florida
      • Coral Springs, Florida, 미국, 33065
        • 모병
        • Advanced Research, LLC
        • 수석 연구원:
          • Sumit Sawhney
        • 연락하다:
      • Miami, Florida, 미국, 33143
        • 아직 모집하지 않음
        • Bioresearch Partners
        • 수석 연구원:
          • Luis Rangel
        • 연락하다:
      • Orlando, Florida, 미국, 32804-4648
        • 아직 모집하지 않음
        • AdventHealth - Cancer Institute - Orlando
        • 연락하다:
        • 수석 연구원:
          • Ahmed Zakari
      • Tamarac, Florida, 미국, 33321
        • 아직 모집하지 않음
        • Florida Clinical Trials Group
        • 수석 연구원:
          • Chintan Gandhi
        • 연락하다:
      • Tampa, Florida, 미국, 33612
        • 아직 모집하지 않음
        • Moffit Cancer Center
        • 수석 연구원:
          • Andrew Kuykendall
        • 연락하다:
    • Georgia
      • Atlanta, Georgia, 미국, 30322
        • 아직 모집하지 않음
        • Emory University
        • 연락하다:
        • 수석 연구원:
          • Anthony Hunter
    • Massachusetts
      • Boston, Massachusetts, 미국, 02111
        • 아직 모집하지 않음
        • Tufts Medical Center
        • 연락하다:
        • 수석 연구원:
          • Parva Bhatt
    • Missouri
      • St Louis, Missouri, 미국, 63110
        • 아직 모집하지 않음
        • Washington University School of Medicine
        • 수석 연구원:
          • Amy Zhou
        • 연락하다:
    • Montana
      • Billings, Montana, 미국, 59101
        • 아직 모집하지 않음
        • St. Vincent Regional Hospital Cancer Centers
        • 수석 연구원:
          • Patrick Cobb
        • 연락하다:
    • New Mexico
      • Albuquerque, New Mexico, 미국, 87102
        • 아직 모집하지 않음
        • University of New Mexico Comprehensive Cancer Center
        • 수석 연구원:
          • Ala Ebaid
        • 연락하다:
    • New York
      • New York, New York, 미국, 10029
        • 아직 모집하지 않음
        • Icahn School of Medicine at Mount Sinai
        • 수석 연구원:
          • John Mascarenhas
        • 연락하다:
      • New York, New York, 미국, 10021
        • 아직 모집하지 않음
        • Memorial Sloan Kettering Cancer Center
        • 수석 연구원:
          • Brian Chernak
        • 연락하다:
    • North Carolina
      • Durham, North Carolina, 미국, 27705
        • 아직 모집하지 않음
        • Duke Blood Cancer Center
        • 수석 연구원:
          • Lindsay Rein
        • 연락하다:
      • Winston-Salem, North Carolina, 미국, 27103
        • 아직 모집하지 않음
        • Novant Health
        • 수석 연구원:
          • James Dugan
        • 연락하다:
    • Ohio
      • Cleveland, Ohio, 미국, 44195
        • 아직 모집하지 않음
        • Cleveland Clinic
        • 수석 연구원:
          • Aaron Gerds
        • 연락하다:
    • Oregon
      • Portland, Oregon, 미국, 97239
        • 아직 모집하지 않음
        • Oregon Health and Science University
        • 연락하다:
        • 수석 연구원:
          • Jessica Stempel
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19107
        • 아직 모집하지 않음
        • Thomas Jefferson University
        • 수석 연구원:
          • Lindsay Wilde
        • 연락하다:
      • Pittsburgh, Pennsylvania, 미국, 15219
        • 아직 모집하지 않음
        • University of Pittsburgh Medical Center
        • 연락하다:
        • 수석 연구원:
          • James Rossetti
      • Pittsburgh, Pennsylvania, 미국, 15224
        • 아직 모집하지 않음
        • Allegheny Health Network Cancer Institute - West Penn Hospital Location
        • 수석 연구원:
          • Anna Koget
        • 연락하다:
    • South Carolina
      • Charleston, South Carolina, 미국, 29425
        • 아직 모집하지 않음
        • Medical University of South Carolina
        • 수석 연구원:
          • Praneeth Baratam
        • 연락하다:
    • Tennessee
      • Nashville, Tennessee, 미국, 37232-0021
        • 아직 모집하지 않음
        • Vanderbilt-Ingram Cancer Center (VICC)-Nashville
        • 수석 연구원:
          • Ashwin Kishtagari
        • 연락하다:
    • Texas
      • Dallas, Texas, 미국, 75246
        • 아직 모집하지 않음
        • Baylor University Medical Center
        • 연락하다:
        • 수석 연구원:
          • Micah Burch
      • Houston, Texas, 미국, 77030
        • 아직 모집하지 않음
        • MD Anderson Cancer Center
        • 수석 연구원:
          • Prithviraj Bose
        • 연락하다:
      • Houston, Texas, 미국, 77090
        • 모병
        • LUMI Research
        • 수석 연구원:
          • David Nguyen
        • 연락하다:
      • Houston, Texas, 미국, 77030
        • 아직 모집하지 않음
        • The University of Utah-Huntsman Cancer Institute
        • 수석 연구원:
          • Srinivas Tantravahi
        • 연락하다:
    • Washington
      • Seattle, Washington, 미국, 98109
        • 아직 모집하지 않음
        • University of Washington
        • 수석 연구원:
          • Anna Halpern
        • 연락하다:
  • 벨기에
      • Antwerp, 벨기에, 2030
        • 아직 모집하지 않음
        • Ziekenhuis aan de Stroom-Cadix
        • 수석 연구원:
          • Nikki Granacher
        • 연락하다:
      • Yvoir, 벨기에, 5530
    • Hainaut
      • La Louvière, Hainaut, 벨기에, 7100
    • Vlaams-Brabant
      • Leuven, Vlaams-Brabant, 벨기에, 3000
        • 아직 모집하지 않음
        • UZ Leuven
        • 수석 연구원:
          • Timothy Devos
        • 연락하다:
    • West-Vlaanderen
      • Roeselare, West-Vlaanderen, 벨기에, 8800
        • 아직 모집하지 않음
        • AZ Delta
        • 수석 연구원:
          • Lien Deleu
        • 연락하다:
  • 불가리아
      • Pleven, 불가리아, 5800
        • 아직 모집하지 않음
        • UMHAT 'Dr. Georgi Stranski', EAD
        • 연락하다:
        • 수석 연구원:
          • Vanya Slavcheva-Popova
      • Plovdiv, 불가리아, 4002
        • 아직 모집하지 않음
        • Dr. Pencho Georgiev - Outpatient Center
        • 수석 연구원:
          • Pencho Georgiev
        • 연락하다:
      • Sofia, 불가리아, 1431
        • 아직 모집하지 않음
        • UMHAT Sv. Ivan Rilski
        • 수석 연구원:
          • Atanas Radinoff
        • 연락하다:
      • Sofia, 불가리아, 1797
        • 아직 모집하지 않음
        • Specialized Hospital for Active Treatment of Haematological Diseases - Sofia
        • 수석 연구원:
          • Martin Donchev
        • 연락하다:
  • 브라질
      • São Paulo, 브라질, 01323-900
        • 아직 모집하지 않음
        • Portuguese Charity of Sao Paulo
        • 수석 연구원:
          • Phillip Scheinberg
        • 연락하다:
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, 브라질, 90610-000
        • 아직 모집하지 않음
        • Hospital Sao Lucas da PUCRS
        • 수석 연구원:
          • Mariza Schaan
        • 연락하다:
      • Porto Alegre, Rio Grande do Sul, 브라질, 90035-903
        • 아직 모집하지 않음
        • Porto Alegre Clinical Hospital (HCPA)
        • 수석 연구원:
          • Laura Maria Fogliatto
        • 연락하다:
      • Porto Alegre, Rio Grande do Sul, 브라질, 90110-270
        • 아직 모집하지 않음
        • Hospital Mae De Deus - Integrated Oncology Center
        • 수석 연구원:
          • Marcelo Capra
        • 연락하다:
    • Rio de Janeiro
      • Rio de Janeiro, Rio de Janeiro, 브라질, 22061080
        • 아직 모집하지 않음
        • Centro de Ensino, Pesquisa e Inovacao do Hospital Sao Lucas (CEPIN HSL RJ / Rede Americas)
        • 연락하다:
        • 수석 연구원:
          • Cristiane Solza
    • Santa Catarina
      • Florianópolis, Santa Catarina, 브라질, 88020-210
        • 아직 모집하지 않음
        • Grupo Elora Pesquisa Clinica
        • 연락하다:
        • 수석 연구원:
          • Jaisson Bortolini
      • Joinville, Santa Catarina, 브라질, 89201-260
        • 아직 모집하지 않음
        • Centro de Hematologia e Oncologia (CHO)
        • 수석 연구원:
          • Marcelo Pitombeira de Lacerda
        • 연락하다:
    • São Paulo
      • Jaú, São Paulo, 브라질, 17210-080
        • 아직 모집하지 않음
        • Hospital Amaral Carvalho (HAC)
        • 수석 연구원:
          • Ederson Mattos
        • 연락하다:
  • 사우디 아라비아
      • Riyadh, 사우디 아라비아, 12372
        • 아직 모집하지 않음
        • King Khalid University Hospital
        • 연락하다:
        • 수석 연구원:
          • Musa Alzahrani
      • Riyadh, 사우디 아라비아, 11211
        • 아직 모집하지 않음
        • King Faisal Specialist Hospital & Research Centre Riyadh
        • 연락하다:
        • 수석 연구원:
          • Marwan Shaheen
  • 스웨덴
      • Stockholm, 스웨덴, 14186
        • 아직 모집하지 않음
        • Karolinska University Hospital
        • 수석 연구원:
          • Anne-Marie Landtblom
        • 연락하다:
      • Örebro, 스웨덴, 70185
        • 아직 모집하지 않음
        • Örebro University Hospital
        • 연락하다:
        • 수석 연구원:
          • Erik Ahlstrand
  • 스페인
      • Barcelona, 스페인, 08035
        • 아직 모집하지 않음
        • Hospital Universitari Vall d'Hebron
        • 수석 연구원:
          • Maria Laura Fox
        • 연락하다:
      • Madrid, 스페인, 28034
        • 아직 모집하지 않음
        • Hospital Ramon y Cajal
        • 연락하다:
        • 수석 연구원:
          • Jose Valentin Garcia-Gutierrez
      • Salamanca, 스페인, 37007
        • 아직 모집하지 않음
        • Universidad de Salamanca - Hospital Universitario de Salamanca
        • 수석 연구원:
          • Jesús María Hernández Rivas
        • 연락하다:
          • Site Contact
          • 전화번호: 626308549
          • 이메일: jmhr@usal.es
      • Valencia, 스페인, 46026
        • 아직 모집하지 않음
        • Hospital Universitari i Politecnic La Fe
        • 수석 연구원:
          • Elvira Mora Castera
        • 연락하다:
    • Barcelona
      • Badalona, Barcelona, 스페인, 8916
        • 아직 모집하지 않음
        • Institut Catala D'oncologia
        • 수석 연구원:
          • Blanca Xicoy Cirici
        • 연락하다:
      • L'Hospitalet de Llobregat, Barcelona, 스페인, 08908
        • 아직 모집하지 않음
        • Institut Catala d'Oncologia Hospital Duran y Renals
        • 연락하다:
        • 수석 연구원:
          • Jasson Villarreal
    • LAS Palmas
      • Las Palmas de Gran Canaria, LAS Palmas, 스페인, 35010
        • 아직 모집하지 않음
        • Hospital Universitario de Gran Canaria Doctor Negrin
        • 수석 연구원:
          • Adrian Segura Diaz
        • 연락하다:
    • M
      • Málaga, M, 스페인, 29003
        • 아직 모집하지 않음
        • Hospital Universitario Virgen de la Victoria
        • 수석 연구원:
          • Regina Garcia-Delgado
        • 연락하다:
  • 아르헨티나
      • Buenos Aires, 아르헨티나, CPC1118AAT
        • 아직 모집하지 않음
        • Hospital Aleman (HA) Deutsches Hospital
        • 연락하다:
        • 수석 연구원:
          • Maria De Los Angeles Vicente Reparaz
      • Córdoba, 아르헨티나, 5000
        • 아직 모집하지 않음
        • BRCR Global
        • 연락하다:
        • 수석 연구원:
          • Karla Di Sisto
    • Buenos Aires
      • Pilar, Buenos Aires, 아르헨티나, B1629AHJ
        • 아직 모집하지 않음
        • Hospital Universitario Austral
        • 연락하다:
        • 수석 연구원:
          • Silvio Carricondo
    • Ciudad Autonoma de BuenosAires
      • Buenos Aires, Ciudad Autonoma de BuenosAires, 아르헨티나, 1405
        • 아직 모집하지 않음
        • Swiss Medical Center Barrio Parque
        • 수석 연구원:
          • Claudio Marcelo Iastrebner
        • 연락하다:
    • Santa Fe Province
      • Rosario, Santa Fe Province, 아르헨티나, 2000
        • 아직 모집하지 않음
        • Instituto Medico de la Fundacion Estudios Clinicos
        • 수석 연구원:
          • Gustavo Jorge Braidot
        • 연락하다:
      • Rosario, Santa Fe Province, 아르헨티나, S2000GAP
        • 아직 모집하지 않음
        • Hospital Privado de Rosario
        • 수석 연구원:
          • Jose Luis Fedele
        • 연락하다:
  • 아일랜드
      • Cork, 아일랜드, T12 DC4A
        • 아직 모집하지 않음
        • Cork University Hospital
        • 연락하다:
        • 수석 연구원:
          • Clodagh Keohane
      • Dublin, 아일랜드, D08 NHY1
        • 아직 모집하지 않음
        • St James's Hospital
        • 수석 연구원:
          • Catherine Flynn
        • 연락하다:
      • Dublin, 아일랜드, D15 W8Y7
        • 아직 모집하지 않음
        • Mater Misericordiae University Hospital
        • 수석 연구원:
          • Su Maung
        • 연락하다:
      • Galway, 아일랜드, H91YR71
        • 아직 모집하지 않음
        • University Hospital Galway
        • 수석 연구원:
          • Janusz Krawczyk
        • 연락하다:
  • 영국
      • London, 영국, SE1 9RT
        • 아직 모집하지 않음
        • Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
        • 수석 연구원:
          • Claire Harrison
        • 연락하다:
      • London, 영국, NW1 2PG
        • 아직 모집하지 않음
        • UCL Cancer Institute - University College London Hospitals NHS Foundation Trust
        • 수석 연구원:
          • Jonathan Lambert
        • 연락하다:
    • East Midlands
      • Lincoln, East Midlands, 영국, LN2 5QY
        • 아직 모집하지 않음
        • United Lincolnshire Teaching Hospitals NHS Trust
        • 수석 연구원:
          • Ciro Rinaldi
        • 연락하다:
    • Leicestershire
      • Leicester, Leicestershire, 영국, LE1 5WW
        • 아직 모집하지 않음
        • University Hospital of Leicester NHS
        • 수석 연구원:
          • Mamta Garg
        • 연락하다:
    • London, City of
      • London, London, City of, 영국, W12 0HS
        • 아직 모집하지 않음
        • Imperial College Healthcare NHS Trust
        • 수석 연구원:
          • Simone Claudiani
        • 연락하다:
    • Tyne and Wear
      • Sunderland, Tyne and Wear, 영국, SR4 7TP
        • 아직 모집하지 않음
        • Sunderland and South Tyneside NHS Foundation Trust
        • 수석 연구원:
          • Scott Marshall
        • 연락하다:
    • W Mids
      • Birmingham, W Mids, 영국
        • 아직 모집하지 않음
        • Birmingham Heartlands Hospital
        • 연락하다:
        • 수석 연구원:
          • Joanne Ewing
  • 오스트리아
      • Linz, 오스트리아, 4020
        • 아직 모집하지 않음
        • Ordensklinikum Linz Elisabethinen
        • 수석 연구원:
          • Veronika Buxhofer-Ausch
        • 연락하다:
    • A
      • Vienna, A, 오스트리아, 1090
        • 아직 모집하지 않음
        • Medizinische Universitat Wien (Medical University of Vienna - Austria)
        • 연락하다:
        • 수석 연구원:
          • Maria-Theresa Krauth
    • Tyrol
      • Innsbruck, Tyrol, 오스트리아, 6020
        • 아직 모집하지 않음
        • Medizinische Universität Innsbruck
        • 연락하다:
        • 수석 연구원:
          • Dominik Wolf
    • Upper Austria
      • Wels, Upper Austria, 오스트리아, 4600
        • 아직 모집하지 않음
        • Klinikum Wels-Grieskirchen
        • 수석 연구원:
          • Sonja Heibl
        • 연락하다:
  • 이스라엘
      • Haifa, 이스라엘, 3436212
        • 아직 모집하지 않음
        • Carmel Medical Center
        • 수석 연구원:
          • Elena Mishchenko
        • 연락하다:
      • Jerusalem, 이스라엘, 9112001
        • 아직 모집하지 않음
        • Hadassah Medical Organization, Hadassah Medical Center, Ein-
        • 수석 연구원:
          • David Lavie
        • 연락하다:
      • Petah Tikva, 이스라엘, 4941492
        • 아직 모집하지 않음
        • Rabin Medical Center
        • 연락하다:
        • 수석 연구원:
          • Adi Shacham-Abulafia
    • North
      • Haifa, North, 이스라엘, 3109601
        • 아직 모집하지 않음
        • Rambam Health Care Campus
        • 연락하다:
        • 수석 연구원:
          • Inna Tzoran
    • TLV
      • Tel Aviv, TLV, 이스라엘, 64239
        • 아직 모집하지 않음
        • The Tel Aviv Sourasky Medical Center
        • 수석 연구원:
          • Ilya Kirgner
        • 연락하다:
  • 이탈리아
      • Ancona, 이탈리아, 60121
        • 아직 모집하지 않음
        • Azienda Ospedaliero-Universitaria delle Marche; SOD Clinica Medica
        • 연락하다:
        • 수석 연구원:
          • Erika Morsia
      • Catania, 이탈리아, 95124
        • 아직 모집하지 않음
        • Policlinico Universitario di Catania
        • 수석 연구원:
          • Giuseppe Palumbo
        • 연락하다:
      • Florence, 이탈리아, 50134
        • 아직 모집하지 않음
        • Azienda Ospedaliera Universitaria Careggi
        • 수석 연구원:
          • Alessandro Maria Vannucchi
        • 연락하다:
      • Torino, 이탈리아, 10126
        • 아직 모집하지 않음
        • AOU Citta della Salute e della Scienza di Torino
        • 연락하다:
        • 수석 연구원:
          • Benevolo Giulia
      • Udine, 이탈리아, 33100
        • 아직 모집하지 않음
        • Azienda Sanitaria Universitaria Friuli Centrale
        • 수석 연구원:
          • Mario Tiribelli
        • 연락하다:
    • BO
      • Bologna, BO, 이탈리아, 40138
        • 아직 모집하지 않음
        • IRCCS - AOU di Bologna - Sant Orsola Malpighi
        • 수석 연구원:
          • FRANCESCA PALANDRI
        • 연락하다:
    • Ferrara
      • Cona, Ferrara, 이탈리아, 44124
        • 아직 모집하지 않음
        • Universitaria di Ferrara Azienda Ospedaliero
        • 연락하다:
        • 수석 연구원:
          • Giuseppe Auteri
    • Forli-Cesena
      • Meldola, Forli-Cesena, 이탈리아, 47014
        • 아직 모집하지 않음
        • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l
        • 수석 연구원:
          • Alessandro Lucchesi
        • 연락하다:
    • Lazio
      • Rome, Lazio, 이탈리아, 00161
        • 아직 모집하지 않음
        • Universita degli Studi di Roma La Sapienza - Umberto I Policlinico di Roma
        • 수석 연구원:
          • Massimo Breccia
        • 연락하다:
      • Rome, Lazio, 이탈리아, 144
        • 아직 모집하지 않음
        • Ospedale S Eugenio
        • 수석 연구원:
          • Elisabetta Abruzzese
        • 연락하다:
    • MI
      • Milan, MI, 이탈리아, 20122
        • 아직 모집하지 않음
        • Fondazione Irccs Ca' Granda Ospedale Maggioe Policlinico Di Milano
        • 수석 연구원:
          • Francesco Passamonti
        • 연락하다:
    • RM
      • Rome, RM, 이탈리아, 00168
        • 아직 모집하지 않음
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
        • 연락하다:
        • 수석 연구원:
          • Elena Rossi
  • 인도
      • Delhi, 인도, 201012
        • 아직 모집하지 않음
        • Max Super Specialty Hospital
        • 수석 연구원:
          • Rayaz Ahmed
        • 연락하다:
    • Haryana
      • Gurgaon, Haryana, 인도, 122001
        • 아직 모집하지 않음
        • Medanta- The Medicity- Gurugram
        • 수석 연구원:
          • Nitin Sood
        • 연락하다:
    • Kerala
      • Kochi, Kerala, 인도, 682041
        • 아직 모집하지 않음
        • Amrita Institute of Medical Sciences
        • 연락하다:
        • 수석 연구원:
          • Neeraj Sidharthan
      • Thiruvananthapuram, Kerala, 인도, 695011
        • 아직 모집하지 않음
        • Regional Cancer Centre
        • 연락하다:
        • 수석 연구원:
          • Sungeeth Thambi
    • Maharashtra
      • Pune, Maharashtra, 인도, 411004
        • 아직 모집하지 않음
        • Sahyadri Super Speciality Hospital Deccan
        • 연락하다:
        • 수석 연구원:
          • Shashikant Janardhan Apte
    • NEW Delhi
      • Rohini, NEW Delhi, 인도, 110085
        • 아직 모집하지 않음
        • Rajiv Gandhi Cancer Institute And Research Centre
        • 수석 연구원:
          • Dinesh Bhurani
        • 연락하다:
    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, 인도, 110029
        • 아직 모집하지 않음
        • All India Institute of Medical Science
        • 연락하다:
        • 수석 연구원:
          • Ranjit Sahoo
    • Tamil Nadu
      • Chennai, Tamil Nadu, 인도, 382424
        • 아직 모집하지 않음
        • Apollo Specialty Hospitals
        • 수석 연구원:
          • Velu Nair
        • 연락하다:
    • Telangana
      • Hyderabad, Telangana, 인도, 500096
        • 아직 모집하지 않음
        • Apollo Hospital Hyderabad
        • 연락하다:
        • 수석 연구원:
          • Padmaja Lokireddy
    • West Bengal
      • Kolkata, West Bengal, 인도, 700 160
        • 아직 모집하지 않음
        • Tata Medical Center, Kolkata
        • 수석 연구원:
          • Arijit Nag
        • 연락하다:
  • 일본
    • Chiba
      • Chiba, Chiba, 일본, 260-8717
        • 아직 모집하지 않음
        • Chiba Cancer Center
        • 수석 연구원:
          • Masahiro Takeuchi
        • 연락하다:
    • Ehime
      • Toon-shi, Ehime, 일본, 791-0295
        • 아직 모집하지 않음
        • Ehime University Hospital
        • 연락하다:
        • 수석 연구원:
          • Katsuto Takenaka
    • Hyōgo
      • Kobe, Hyōgo, 일본, 650-0047
        • 아직 모집하지 않음
        • Kobe City Medical Center General Hospital
        • 연락하다:
          • Site Contact
          • 전화번호: 78-302-4321
        • 수석 연구원:
          • Yuya Nagai
    • Ibaraki
      • Hitachi, Ibaraki, 일본, 317-0077
    • Mie-ken
      • Tsu, Mie-ken, 일본, 514-8507
        • 아직 모집하지 않음
        • Mie University Hospital
        • 연락하다:
          • Site Contact
          • 전화번호: 81(0)59-232-1111
        • 수석 연구원:
          • Yuka Sugimoto
    • Miyazaki
      • Miyazaki, Miyazaki, 일본, 889-1692
        • 아직 모집하지 않음
        • University of Miyazaki Hospital
        • 연락하다:
          • Site Contact
          • 전화번호: 81-985-85-1510
        • 수석 연구원:
          • Kazuya Shimoda
    • Tokyo
      • Bunkyo-Ku, Tokyo, 일본, 113-8677
        • 아직 모집하지 않음
        • Tokyo Metropolitan Komagome Hospital
        • 연락하다:
        • 수석 연구원:
          • Noriko Doki
    • Yamanashi
      • Chuo-shi, Yamanashi, 일본, 409-3898
        • 아직 모집하지 않음
        • University of Yamanashi Hospital
        • 수석 연구원:
          • Keita Kirito
        • 연락하다:
  • 체코
      • Prague, 체코, 134 00
        • 아직 모집하지 않음
        • Fakultni nemocnice Kralovske Vinohrady
        • 수석 연구원:
          • Olga Cerna
        • 연락하다:
    • CZ
      • Hradec Králové, CZ, 체코, 50005
        • 아직 모집하지 않음
        • Fakultni nemocnice Hradec Kralove
        • 수석 연구원:
          • Petra Belohlavkova
        • 연락하다:
      • Prague, CZ, 체코, 12808
        • 아직 모집하지 않음
        • Vseobecna fakultni nemocnice Praha
        • 수석 연구원:
          • Anna Jonasova
        • 연락하다:
    • Czech Republic
      • Brno, Czech Republic, 체코, 625 00
        • 아직 모집하지 않음
        • Masaryk University Hospital Brno, Department of Internal Medicine, Hematology and Oncology
        • 연락하다:
        • 수석 연구원:
          • Barbora Weinbergerova
  • 칠레
    • Biobio
      • Concepción, Biobio, 칠레, 4030000
        • 아직 모집하지 않음
        • Hospital Cliniico Regional de Concepcion Dr
        • 수석 연구원:
          • Monica Romero
        • 연락하다:
    • Coquimbo Region
      • La Serena, Coquimbo Region, 칠레, 01697
        • 아직 모집하지 않음
        • IC La Serena Research
        • 수석 연구원:
          • Cleiden Villegas
        • 연락하다:
    • La Florida
      • Santiago, La Florida, 칠레, 8241479
        • 아직 모집하지 않음
        • Icegclinic
        • 연락하다:
        • 수석 연구원:
          • Carlos Avendano
    • Santiago Metropolitan
      • Las Condes, Santiago Metropolitan, 칠레, 7560908
        • 아직 모집하지 않음
        • Immunocel
        • 수석 연구원:
          • Alejandro Berkovits
        • 연락하다:
      • Santiago, Santiago Metropolitan, 칠레, 7850000
        • 아직 모집하지 않음
        • Centro de Oncologia de Precision
        • 연락하다:
        • 수석 연구원:
          • Ignacio Corvalan
  • 캐나다
    • Ontario
      • Hamilton, Ontario, 캐나다, L8V 5C2
        • 아직 모집하지 않음
        • Juravinski Cancer Centre
        • 수석 연구원:
          • Hillis Christopher
        • 연락하다:
      • Toronto, Ontario, 캐나다, M5G 2M9
        • 아직 모집하지 않음
        • Princess Margaret Cancer Centre
        • 연락하다:
        • 수석 연구원:
          • Dawn Maze
    • Quebec
      • Montreal, Quebec, 캐나다, H4A 3J1
        • 아직 모집하지 않음
        • McGill University Health Center
        • 수석 연구원:
          • Jonathan How
        • 연락하다:
      • Montreal, Quebec, 캐나다, H3T1E2
        • 아직 모집하지 않음
        • Jewish General Hospital
        • 수석 연구원:
          • Shireen Sirhan
        • 연락하다:
  • 콜롬비아
    • Antioquia
      • Medellín, Antioquia, 콜롬비아, 0000000
        • 아직 모집하지 않음
        • Hospital Pablo Tobon Uribe
        • 연락하다:
        • 수석 연구원:
          • Kenny Galvez
    • Atlántico
      • Barranquilla, Atlántico, 콜롬비아, 080002
        • 아직 모집하지 않음
        • Clinica General del Norte De Barranquilla
        • 연락하다:
        • 수석 연구원:
          • Arturo Guzman
    • Bogota D.C.
      • Bogotá, Bogota D.C., 콜롬비아, 110121
        • 아직 모집하지 않음
        • Los Cobos Medical Center
        • 연락하다:
        • 수석 연구원:
          • Jheremy Reyes
    • Cundinamarca
      • Bogota, Cundinamarca, 콜롬비아, 11011
        • 아직 모집하지 않음
        • Funcacion santa Fe De Bogota
        • 연락하다:
        • 수석 연구원:
          • Claudia Agudelo
  • 터키 (Türkiye)
      • Istanbul, 터키 (Türkiye), 34381
        • 아직 모집하지 않음
        • Istanbul Florence Nightingale Hospital
        • 연락하다:
        • 수석 연구원:
          • Omur Sevindik
      • Istanbul, 터키 (Türkiye), 34303
        • 아직 모집하지 않음
        • Istanbul University-CerrahpaAYa, CerrahpaAYa Faculty of Medicine
        • 연락하다:
        • 수석 연구원:
          • Ahmet Emre Eskazan
    • Ankara
      • Çankaya, Ankara, 터키 (Türkiye), 06800
        • 아직 모집하지 않음
        • Ankara Bilkent City Hospital
        • 연락하다:
        • 수석 연구원:
          • Marve Pamukcuoglu
    • Mezitli
      • Mersin, Mezitli, 터키 (Türkiye), 33000
        • 아직 모집하지 않음
        • VM Medical Park Mersin Hospital
        • 수석 연구원:
          • Anil Tombak
        • 연락하다:
  • 폴란드
    • Greater Poland Voivodeship
      • Poznan, Greater Poland Voivodeship, 폴란드, 60-192
        • 아직 모집하지 않음
        • Pratia Poznań
        • 수석 연구원:
          • Anna Hoppe
        • 연락하다:
    • Kuyavian-Pomeranian Voivodeship
      • Torun, Kuyavian-Pomeranian Voivodeship, 폴란드, 87-100
        • 아직 모집하지 않음
        • Wojewodzki Szpital Zespolony Im L Rydygiera
        • 수석 연구원:
          • Dominik Chraniuk
        • 연락하다:
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, 폴란드, 02-172
        • 아직 모집하지 않음
        • MTZ Clinical Research Powered by PRATIA
        • 수석 연구원:
          • Krzysztof Madry
        • 연락하다:
    • Silesian Voivodeship
      • Chorzów, Silesian Voivodeship, 폴란드, 41-500
        • 아직 모집하지 않음
        • Zespol Szpitali Miejskich w Chorzowie
        • 연락하다:
        • 수석 연구원:
          • Piotr Malecki
      • Katowice, Silesian Voivodeship, 폴란드, 40-519
        • 아직 모집하지 않음
        • Pratia Oncology Katowice
        • 수석 연구원:
          • Sebastian Grosicki
        • 연락하다:
    • Łódź Voivodeship
      • Lodz, Łódź Voivodeship, 폴란드, 93-513
        • 아직 모집하지 않음
        • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Oddzial Hematologii
        • 연락하다:
        • 수석 연구원:
          • Joanna Gora-Tybor
  • 프랑스
    • Alpes Maritimes
      • Nice, Alpes Maritimes, 프랑스, 6002
        • 아직 모집하지 않음
        • Chu De Nice
        • 수석 연구원:
          • Michael Loschi
        • 연락하다:
    • Auvergne-Rhône-Alpes
      • Pierre-Bénite, Auvergne-Rhône-Alpes, 프랑스, 69495
        • 아직 모집하지 않음
        • Centre Hospitalier LYON SUD
        • 수석 연구원:
          • Vincent Alcazer
        • 연락하다:
    • Bas Rhin
      • Strasbourg, Bas Rhin, 프랑스, 67200
        • 아직 모집하지 않음
        • CHU de Strasbourg
        • 연락하다:
        • 수석 연구원:
          • Shanti Ame
    • Bouches-du-Rhone
      • Marseille, Bouches-du-Rhone, 프랑스, 13009
        • 아직 모집하지 않음
        • Institut Paoli Calmettes
        • 연락하다:
        • 수석 연구원:
          • Jerome Rey
    • Finistere
      • Brest, Finistere, 프랑스, 29609
        • 아직 모집하지 않음
        • Centre Hospitalier Regional Universitaire Brest Hopital Morvan
        • 수석 연구원:
          • Jean-Christophe Ianotto
        • 연락하다:
    • Gironde
      • Pessac, Gironde, 프랑스, 33600
        • 아직 모집하지 않음
        • CHU de Bordeaux
        • 연락하다:
        • 수석 연구원:
          • Clemence Mediavilla
    • Nord
      • Lille, Nord, 프랑스, 59037
        • 아직 모집하지 않음
        • Centre Hospitalier Regional Universitaire de Lille
        • 연락하다:
        • 수석 연구원:
          • Mathieu Wemeau
    • Paris
      • Paris, Paris, 프랑스, 75015
        • 아직 모집하지 않음
        • Assistance Publique Hopitaux De Paris
        • 연락하다:
        • 수석 연구원:
          • Lina Benajiba
    • Vienne
      • Poitiers, Vienne, 프랑스, 86021
  • 헝가리
    • HB
      • Debrecen, HB, 헝가리, 4032
        • 아직 모집하지 않음
        • Debreceni Egyetem Klinikai Kozpont Belgyogyaszati Klinika
        • 수석 연구원:
          • Arpad Illes
        • 연락하다:
    • Komarom-Esztergom VArmegye
      • Tatabánya, Komarom-Esztergom VArmegye, 헝가리, 2800
        • 아직 모집하지 않음
        • Komárom-Esztergom Vármegyei Szent Borbála Kórház
        • 수석 연구원:
          • Zsofia Simon
        • 연락하다:
  • 호주
    • Adelaide, SA
      • Bedford Park, Adelaide, SA, 호주, 5042
        • 아직 모집하지 않음
        • Flinders Medical Centre
        • 수석 연구원:
          • David Ross
        • 연락하다:
    • New South Wales
      • Coffs Harbour, New South Wales, 호주, 2450
        • 아직 모집하지 않음
        • Mid North Coast Cancer Institute (MNCCI)
        • 수석 연구원:
          • Kyle Crassini
        • 연락하다:
      • Cudgen, New South Wales, 호주, 2487
        • 아직 모집하지 않음
        • Tweed Valley Hospital
        • 수석 연구원:
          • Steven Wong
        • 연락하다:
      • Kogarah, New South Wales, 호주, 2217
        • 아직 모집하지 않음
        • South Eastern Sydney Local Health District
        • 연락하다:
        • 수석 연구원:
          • Sundreswran (Sundra) Ramanathan

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  1. Aged ≥18 years at the time of signing the informed consent form (ICF).
  2. Able to understand the purpose and risks of the trial and voluntarily sign an ICF.
  3. Diagnosed with primary myelofibrosis (PMF), post-essential thrombocythemia (post-ET MF) or post-polycythemia vera (post-PV MF) according to the 2022 WHO criteria (WHO Classification of Tumours Editorial Board 2024), confirmed by local pathology report.
  4. Transfusion status as assessed in the 12 weeks immediately preceding randomization classified as Transfusion Dependent: 3 to 8 RBC units over 12 weeks.
  5. Receiving ruxolitinib (as approved in the country of the trial site) as the standard of care treatment for MF for at least 12 consecutive weeks, and on a stable daily dose for at least the 8 weeks immediately preceding the date of randomization.
  6. Eastern Cooperative Oncology Group score less than or equal to (≤) 2.

Exclusion Criteria:

  1. Prior treatment with luspatercept, sotatercept, or other transforming growth factor beta inhibitors or activin receptor ligand traps.

  2. Systemic treatment within 28 days before randomization with any of the following:

    1. Androgens (including danazol). Participants on stable androgen dosing for hypogonadism for ≥8 weeks are allowed.
    2. erythropoiesis-stimulating agents.
    3. granulocyte colony stimulating factor or granulocyte-macrophage colony stimulating factor.
    4. High dose corticosteroids. Participants on stable chronic steroid doses of prednisone ≤10 mg/day or corticosteroid equivalent for ≥4 weeks are allowed. Other treatments for autoimmune diseases may be allowed upon medical monitor review.
    5. Hydroxyurea.
    6. Immunomodulatory drugs (for example, thalidomide, pomalidomide, or lenalidomide).
    7. Interferon.
    8. Thrombopoietin receptor agonists.
    9. Any investigational drug, including antihemojuvelin antibody. If the half-life of the investigational product is known, the exclusionary period prior to randomization is equal to 5 half-lives of the investigational product or 28 days, whichever is longer.
  3. Initiation of new iron chelation therapy or dose adjustments to existing iron chelation therapy ≤8 weeks prior to randomization. Participants on stable doses of iron chelation therapy for ≥8 weeks are allowed.
  4. Clinically significant anemia that is due to causes other than MF or Janus kinase (JAK) inhibitor therapy (for example, thalassemia, iron deficiency, vitamin B12 and/or folate deficiencies, autoimmune or hemolytic anemia, infections, or any active clinically significant bleeding or sequestration).
  5. Receipt of RBC transfusion for any reason(s) other than underlying MF within 12 weeks before randomization.
  6. Life expectancy <12 months per investigator's judgment.

  7. Clinically significant cardiovascular disease, defined as:

    1. New York Heart Association heart disease Class III or IV;
    2. Fridericia corrected QT interval >500 millisecond (ms) during screening;
    3. Uncontrolled arrhythmia, myocardial infarction, or unstable angina within 6 months before screening.
  8. Uncontrolled hypertension, defined as repeated elevations of systolic blood pressure of ≥160 millimetres of mercury (mmHg) and/or diastolic blood pressure ≥100 mmHg despite adequate treatment.
  9. Medical history of thromboembolic events within 6 months before screening, including history of cerebrovascular accident (including ischemic, embolic, and hemorrhagic cerebrovascular accident), transient ischemic attack, deep venous thrombosis (including proximal and distal), pulmonary or arterial embolism, arterial thrombosis, or other venous thrombosis. Participants with prior superficial thrombophlebitis are allowed.

  10. Prior history of malignancies, other than MF. Participants who are free of other malignant disease for ≥2 years and have completed treatment, including maintenance, are allowed. Participants with a history or concurrent diagnosis of the following conditions are allowed if not requiring systemic therapy:

    1. Basal or squamous cell carcinoma of the skin;
    2. Carcinoma in situ of the cervix;
    3. Carcinoma in situ of the breast; and/or
    4. Incidental histologic finding of prostate cancer (T1a or T1b using the Tumour, Node, and Metastasis (TNM) staging system);
    5. Early papillary thyroid cancer (stage I [T1-T2, N0, M0]).
  11. History of solid organ or bone marrow transplantation.
  12. Active infection requiring intravenous antibiotics within 28 days or oral antibiotics within 7 days before randomization. Prophylactic antibiotics and/or antifungals for neutropenia are allowed.
  13. Known positivity for Human Immunodeficiency Virus (HIV), active hepatitis B virus (HBV), or active hepatitis C virus (HCV). Participants without known history of HIV, HBV, and/or HCV do not require further testing, unless testing is mandated per local guidelines.
  14. Body mass index ≥40 kilograms per square meter (kg/m^2).
  15. Major surgery within 28 days before randomization.
  16. History of allergy/anaphylaxis to recombinant proteins, investigational product, or excipients (refer to the current elritercept investigator's brochure for a list of excipients), or ruxolitinib.

  17. Any of the following local laboratory abnormalities:

    1. Absolute neutrophil count <500/microliter (μL) (0.5×109/ liter (L)).
    2. Platelet count <50,000/μL (50×109/L) or >1,000,000/μL (1000×109/L).
    3. Blasts >5% as assessed in peripheral blood at screening or ≥10% in any historical bone marrow assessments. Participants with isolated transient elevations of peripheral blood blasts may be eligible after discussion between the investigator and medical monitor to confirm the blast count is not indicative of disease progression.
    4. Serum aspartate aminotransferase or alanine aminotransferase ≥3× the upper limit of normal (ULN).
    5. Total bilirubin ≥2×ULN. Participants with known history of Gilbert syndrome with unconjugated bilirubin less than (<) 3×ULN are allowed. Higher levels if attributed to active RBC precursor destruction within the bone marrow (ineffective erythropoiesis) may be allowed upon medical monitor review.
    6. Estimated glomerular filtration rate <30 milliliters per minute per 1.73 square meters (mL/min/1.73 m^2) as determined by the Chronic Kidney Disease Epidemiology Collaboration equation.
    7. Ferritin ≤50 micrograms per liter (μg/L).
    8. Folate ≤2.0 nanograms per milliliter (ng/mL).
    9. Vitamin B12 ≤200 picograms per milliliter (pg/mL).
  18. Ongoing participation in another interventional clinical trial.
  19. Participant is unwilling or, in the opinion of the investigator, the participant is unable to comply with the requirements of the protocol.
  20. Is a person of childbearing potential but does not agree to use at least 1 form of highly effective contraception from the time of signing the ICF until at least 60 days after the last dose of elritercept or placebo.
  21. Participants of male birth who are fertile and who have partners of childbearing potential, who do not agree to use acceptable barrier contraception, that is, a male condom, during the entire treatment period until at least 60 days after the last dose of elritercept or placebo.
  22. If applicable, participant with a positive serum pregnancy test during the screening period or known to be pregnant or a lactating participant who does not agree to forego breastfeeding during the entire treatment period until at least 60 days after the last dose of elritercept or placebo.
  23. For participants in France: Persons under court protection, persons not affiliated with a social security system, and protected adults.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Elritercept
Participants will receive elritercept at a starting dose of 3.75 milligrams per kilogram (mg/kg) subcutaneously (SC) once every 4 weeks (Q4W) on Day 1 of each 28-day cycle for approximately 36 weeks during the double-blinded treatment period, with possible up-titration to 5.0 mg/kg from Cycle 3 Day 1 based on response and safety/tolerability. Participants may continue to receive elritercept during the extended open-label treatment period.
의약품: Elritercept
Elritercept, SC, injection
다른 이름들:
  • 타크-226
위약 비교기: Placebo
Participants will receive elritercept-matching placebo with equivalent volume to elritercept SC Q4W on Day 1 of each 28-day cycle for approximately 36 weeks during the double-blinded treatment period. Eligible participants may initiate elritercept at a starting dose of 3.75 mg/kg SC Q4W on Day 1 of each 28-day cycle during the extended open-label treatment period, with possible up-titration to 5.0 mg/kg after 2 cycles, based on response and safety/tolerability.
의약품: Elritercept
Elritercept, SC, injection
다른 이름들:
  • 타크-226
의약품: Placebo
Elritercept-matching placebo

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Proportion of Participants Who Are Red Blood Cell-Transfusion Independent (RBC-TI) for Any Consecutive Greater Than or Equal to (≥) 12-Week Period During the 36-Week Double-Blinded Treatment Period
기간: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
RBC-TI is defined as no RBC transfusions administered for the specified time period during study treatment.
From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)

2차 결과 측정

결과 측정
측정값 설명
기간
Proportion of Participants Who Achieve ≥50 Percent (%) Reduction in RBC Transfusion Burden From Baseline Over Any Consecutive 12-Week Period
기간: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
Proportion of Participants Who Are RBC-TI for Any Consecutive ≥16-Week Period
기간: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
RBC-TI is defined as no RBC transfusions administered for the specified time period during study treatment.
From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
Proportion of Participants Who Are RBC-TI for Any Consecutive ≥12-Week Period With Concurrent Mean Hemoglobin (Hgb) Increase ≥1.5 Grams per Deciliter (g/dL) From Baseline
기간: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
RBC-TI is defined as no RBC transfusions administered for the specified time period during study treatment.
From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
Proportion of Participants Who Are RBC-TI for Any Consecutive ≥24-Week Period
기간: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
RBC-TI is defined as no RBC transfusions administered for the specified time period during study treatment.
From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
Proportion of Participants Who Are RBC-TI for Any Consecutive ≥12-Week Period With Concurrent Mean Hgb Increase of ≥1.0 g/dL and ≥2.0 g/dL From Baseline
기간: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
RBC-TI is defined as no RBC transfusions administered for the specified time period during study treatment.
From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
Proportion of Participants Who Are RBC-TI for Any Consecutive 16- or 24-Week Period With a Concurrent Mean Hgb Increase of ≥1.0 g/dL, ≥1.5 g/dL, and ≥2.0 g/dL From Baseline
기간: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
RBC-TI is defined as no RBC transfusions administered for the specified time period during study treatment.
From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
Maximum Duration of RBC-TI for Participants Who Achieved RBC-TI for a Consecutive ≥12 Weeks
기간: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
RBC-TI is defined as no RBC transfusions administered for the specified time period during study treatment.
From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
Maximum Duration of RBC-TI With Concurrent Mean Hgb Increase of ≥1.5 g/dL for Participants Who Achieved Consecutive ≥12 Weeks RBC-TI With Concurrent Mean Hgb Increase of ≥1.5 g/dL
기간: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
RBC-TI is defined as no RBC transfusions administered for the specified time period during study treatment.
From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
Time to Onset of Anemia Response
기간: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
Time to onset of anemia response is defined as the duration between the date of randomization and the date participant first achieved anemia response status. Anemia response is evaluated as: achievement of RBC-TI for any consecutive ≥12-week, ≥16-week, or ≥24-week period or ≥50% reduction in red blood cell transfusion burden from baseline over any consecutive 12 weeks.
From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
Mean Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0 - Fatigue 7a T-Score at Week 36
기간: Baseline, Week 36
PROMIS Short Form v1.0 - Fatigue 7a is a 7-item, patient-reported measure designed to assess fatigue symptoms and impact over the past 7 days. Response options are on a 5-point scale from never (1) to always (5). Raw scores are computed by summing responses to all 7 items and then converted to a standardized T-score on a scale from 0 to 100 with a mean of 50 and SD of 10 with higher scores representing worse fatigue. T-scores can be produced using a conversion table available from the instrument developer or using response pattern scoring performed by the Health Measures Scoring Service.
Baseline, Week 36
Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Fatigue Scale Score at Week 36
기간: Baseline, Week 36
EORTC QLQ-C30 is a 30-item, participant-reported multidomain questionnaire designed to assess functioning, wellbeing, and symptom experience of participants with cancer. The questionnaire's items are divided among 5 multi-item scales measuring functioning (physical, role, emotional, cognitive, and social), 3 multi-item scales measuring symptoms (fatigue, nausea/vomiting, and pain), 6 items measuring symptoms (dyspnea, insomnia, appetite loss, constipation, and diarrhea) as well as financial difficulties, and a 2-item scale measuring global health status (GHS))/quality of life (QoL). Items included in GHS/QoL scale use a 7-point response metric ranging from very poor to excellent, while other items use a 4-point response metric with categories including not at all, a little, quite a bit, and very much. Scale scores are transformed to range from 0 to 100 with higher scores indicating better functioning, GHS/QoL, or worse symptomatology.
Baseline, Week 36
Proportion of Participants With Meaningful Improvement and Meaningful Deterioration in PROMIS Short Form v1.0 - Fatigue 7a T-score
기간: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
PROMIS Short Form v1.0 - Fatigue 7a is a 7-item, patient-reported measure designed to assess fatigue symptoms and impact over the past 7 days. Response options are on a 5-point scale from never (1) to always (5). Raw scores are computed by summing responses to all 7 items and then converted to a standardized T-score on a scale from 0 to 100 with a mean of 50 and SD of 10 with higher scores representing worse fatigue. T-scores can be produced using a conversion table available from the instrument developer or using response pattern scoring performed by the Health Measures Scoring Service. Score cutoffs to define meaningful improvement and meaningful deterioration will be determined prior to the primary analysis based on analysis of blinded trial data in accordance with a prespecified psychometric analysis plan.
From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
Time to Meaningful Improvement and Meaningful Deterioration in PROMIS Short Form v1.0 - Fatigue 7a T-Score From Baseline
기간: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
PROMIS Short Form v1.0 - Fatigue 7a is a 7-item, patient-reported measure designed to assess fatigue symptoms and impact over the past 7 days. Response options are on a 5-point scale from never (1) to always (5). Raw scores are computed by summing responses to all 7 items and then converted to a standardized T-score on a scale from 0 to 100 with a mean of 50 and SD of 10 with higher scores representing worse fatigue. T-scores can be produced using a conversion table available from the instrument developer or using response pattern scoring performed by the Health Measures Scoring Service. Score cutoffs to define meaningful improvement and meaningful deterioration will be determined prior to the primary analysis based on analysis of blinded trial data in accordance with a prespecified psychometric analysis plan.
From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
Proportion of Participants With Meaningful Improvement and Meaningful Deterioration in EORTC QLQ-C30 Fatigue Scale Score
기간: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
EORTC QLQ-C30 is a 30-item, participant-reported multidomain questionnaire designed to assess functioning, wellbeing, and symptom experience of participant with cancer. The items are divided among 5 multi-item scales measuring functioning (physical, role, emotional, cognitive, and social), 3 multi-item scales measuring symptoms (fatigue, nausea/vomiting, pain), 6 items measuring symptoms (dyspnea, insomnia, appetite loss, constipation, diarrhea) as well as financial difficulties, and a 2-item scale measuring GHS and QoL. Items included in GHS/QoL scale use a 7-point response metric ranging from very poor to excellent, while other items use a 4-point response metric, categories including not at all, a little, quite a bit, and very much. Scale scores are transformed to range from 0 to 100 with higher scores indicating better functioning, better GHS/QoL, or worse symptomatology. Score cutoffs to define meaningful improvement/deterioration to be determined before primary analysis.
From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
Time to Meaningful Improvement and Meaningful Deterioration in EORTC QLQ-C30 Fatigue Scale Score From Baseline
기간: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
EORTC QLQ-C30 is a 30-item, participant-reported multidomain questionnaire designed to assess functioning, wellbeing, and symptom experience of participant with cancer. The items are divided among 5 multi-item scales measuring functioning (physical, role, emotional, cognitive, social), 3 multi-item scales measuring symptoms (fatigue, nausea/vomiting, pain), 6 items measuring symptoms (dyspnea, insomnia, appetite loss, constipation, diarrhea) as well as financial difficulties, and a 2-item scale measuring GHS and QoL. Items included in GHS/QoL scale use a 7-point response metric ranging from very poor to excellent, while other items use a 4-point response metric, categories including not at all, a little, quite a bit, and very much. Scale scores are transformed to range from 0 to 100 with higher scores indicating better functioning, better GHS/QoL, or worse symptomatology. Score cutoffs to define meaningful improvement/deterioration to be determined before primary analysis.
From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
Mean Changes From Baseline in Myelofibrosis Symptom Assessment Form (MFSAF) v4.0 7-Item Total Symptom Score at Week 36
기간: Baseline, Week 36
MFSAF v4.0 is a unidimensional measure assessing 7 core MF symptoms: fatigue, night sweats, itching, abdominal discomfort, pain under ribs, early satiety, and bone pain. The questionnaire asks participants to rate each symptom at its worst during the past 7 days on a 0 to 10 numeric rating scale ranging from absent (0) to worst imaginable (10). The Total Symptom Score (TSS) is calculated as the average of the 7 individual item responses multiplied by 7, yielding a score range of 0 to 70 with higher scores representing worse symptom severity.
Baseline, Week 36
Proportion of Participants Achieving Confirmed 50% Reduction in MFSAF v4.0 Total Symptom Score (TSS50)
기간: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
MFSAF v4.0 is a unidimensional measure assessing 7 core MF symptoms: fatigue, night sweats, itching, abdominal discomfort, pain under ribs, early satiety, and bone pain. The questionnaire asks participants to rate each symptom at its worst during the past 7 days on a 0 to 10 numeric rating scale ranging from absent (0) to worst imaginable (10). The TSS is calculated as the average of the 7 individual item responses multiplied by 7, yielding a score range of 0 to 70 with higher scores representing worse symptom severity.
From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
Time to Symptom Response in MFSAF TSS50 From Baseline
기간: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
MFSAF v4.0 is a unidimensional measure assessing 7 core MF symptoms: fatigue, night sweats, itching, abdominal discomfort, pain under ribs, early satiety, and bone pain. The questionnaire asks participants to rate each symptom at its worst during the past 7 days on a 0 to 10 numeric rating scale ranging from absent (0) to worst imaginable (10). The TSS is calculated as the average of the 7 individual item responses multiplied by 7, yielding a score range of 0 to 70 with higher scores representing worse symptom severity.
From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
Mean Change From Baseline EORTC QLQ-C30 Physical Functioning Scale Score at Week 36
기간: Baseline, Week 36
EORTC QLQ-C30 is a 30-item, participant-reported multidomain questionnaire designed to assess functioning, wellbeing, and symptom experience of participant with cancer. The questionnaire's items include 5 multi-item scales measuring functioning (physical, role, emotional, cognitive, and social). These items use a 4-point response metric with categories including not at all, a little, quite a bit, and very much. Scale scores are transformed to range from 0 to 100 with higher scores indicating better functioning.
Baseline, Week 36
Proportion of Participants With Meaningful Improvement and Meaningful Deterioration in EORTC QLQ-C30 Physical Functioning Scale Score
기간: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
EORTC QLQ-C30 is a 30-item, participant-reported multidomain questionnaire designed to assess functioning, wellbeing, and symptom experience of participant with cancer. The questionnaire's items include 5 multi-item scales measuring functioning (physical, role, emotional, cognitive, and social). These items use a 4-point response metric with categories including not at all, a little, quite a bit, and very much. Scale scores are transformed to range from 0 to 100 with higher scores indicating better functioning. Score cutoffs to define meaningful improvement and meaningful deterioration will be determined prior to the primary analysis based on analysis of blinded trial data in accordance with a prespecified psychometric analysis plan.
From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
Time to Meaningful Improvement and Meaningful Deterioration in EORTC QLQ-C30 Physical Functioning Scale Score From Baseline
기간: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
EORTC QLQ-C30 is a 30-item, participant-reported multidomain questionnaire designed to assess functioning, wellbeing, and symptom experience of participant with cancer. The questionnaire's items include 5 multi-item scales measuring functioning (physical, role, emotional, cognitive, and social). These items use a 4-point response metric with categories including not at all, a little, quite a bit, and very much. Scale scores are transformed to range from 0 to 100 with higher scores indicating better functioning. Score cutoffs to define meaningful improvement and meaningful deterioration will be determined prior to the primary analysis based on analysis of blinded trial data in accordance with a prespecified psychometric analysis plan.
From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
Proportion of Participants With Platelet Response During the 36-Week Double-Blinded Treatment Period
기간: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
Platelet response includes a mean increase of ≥30×10^9/ liter (L) from baseline, a >50% increase from baseline with a count ≥50×10^9/L, and conversion from <100 to ≥100×10^9/L, each sustained for ≥12 weeks.
From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
Proportion of Participants Achieving Spleen Volume Reduction (SVR) From Baseline as Measured by Computed Tomography/Magnetic Resonance Imaging (CT/MRI) During the 36-Week Double-Blinded Treatment Period
기간: From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
Proportion of participants achieving SVR of ≥10%, ≥25%, or ≥35% will be presented for this outcome measure.
From Cycle 1 Day 1 through Week 36 (each cycle is 28 days)
Proportion of Participants Who Develop Accelerated Phase (AP) MF
기간: Up to approximately 7 years
Up to approximately 7 years
Time to Progression in Participants Who Develop AP MF
기간: Up to approximately 7 years
Up to approximately 7 years
Proportion of Participants Who Develop Blast Phase (BP) MF
기간: Up to approximately 7 years
Up to approximately 7 years
Time to Progression in Participants Who Develop BP MF
기간: Up to approximately 7 years
Up to approximately 7 years
Plasma Concentration-Time Data for Participants Treated With Elritercept
기간: At multiple time points from Cycle 1 Day 1 (each cycle is 28 days) up to approximately 7 years
At multiple time points from Cycle 1 Day 1 (each cycle is 28 days) up to approximately 7 years
Proportion of Participants Treated With Elritercept who Have Antidrug Antibodies
기간: At multiple time points from Cycle 1 Day 1 (each cycle is 28 days) up to approximately 7 years
At multiple time points from Cycle 1 Day 1 (each cycle is 28 days) up to approximately 7 years
Overall Survival (OS)
기간: From randomization to 7 years
OS is defined as the time from randomization to the date of death due to any cause.
From randomization to 7 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

Takeda

수사관

  • 연구 책임자: Study Director, Takeda

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

유용한 링크

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 9월 2일

기본 완료 (추정된)

2029년 12월 7일

연구 완료 (추정된)

2034년 3월 30일

연구 등록 날짜

최초 제출

2026년 5월 29일

QC 기준을 충족하는 최초 제출

2026년 5월 29일

처음 게시됨 (실제)

2026년 6월 3일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 8월 24일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 8월 20일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

  • TAK-226-3002
  • 2026-525660-17-00 (씨티스)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

IPD 공유 액세스 기준

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ICF
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다